Evaluation of the sarcopenia quality of life (SarQoL) questionnaire in community dwelling outpatient postmenopausal hungarian women

[1] Baumgartner RN(1998)Epidemiology of sarcopenia among the elderly in New Mexico Am J Epidemiol 147 755-63

[2] Koehler KM(2012)Frailty and sarcopenia: definitions and outcome parameters Osteoporos Int 23 1839-48

[3] Gallagher D(2022)Prevalence of sarcopenia in community dwelling outpatient postmenopausal hungarian women BMC Musculoskelet Disord 23 207-60

[4] Romero L(2003)Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia J Appl Physiol (1985) 95 1851-62

[5] Heymsfield SB(2006)Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study J Am Geriatr Soc 54 56-59

[6] Ross RR(2010)Sarcopenia: etiology, clinical consequences, intervention, and assessment Osteoporos Int 21 543-92

[7] Garry PJ(1978)Long-term treatment of Parkinson’s disease with L-Dopa and dopadecarboxylase inhibitor: therapeutic results and side effects Acta Neurol Scand 57 186-9

[8] Lindeman RD(1971)An attempt to include quality of life in evaluation of survival in bronchial cancer therapy Bronches 21 215-63

[9] Cooper C(1999)Assessing quality of life in clinical research from where have we come and where are we going? J Clin Epidemiol 52 355-22

[10] Dere W(1984)The development of a method for assessing the quality of life of cancer patients Br J Cancer 50 13-70

[1] Baumgartner RN(1998)Epidemiology of sarcopenia among the elderly in New Mexico Am J Epidemiol 147 755-63

[2] Koehler KM(2012)Frailty and sarcopenia: definitions and outcome parameters Osteoporos Int 23 1839-48

[3] Gallagher D(2022)Prevalence of sarcopenia in community dwelling outpatient postmenopausal hungarian women BMC Musculoskelet Disord 23 207-60

[4] Romero L(2003)Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia J Appl Physiol (1985) 95 1851-62

[5] Heymsfield SB(2006)Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study J Am Geriatr Soc 54 56-59

[6] Ross RR(2010)Sarcopenia: etiology, clinical consequences, intervention, and assessment Osteoporos Int 21 543-92

[7] Garry PJ(1978)Long-term treatment of Parkinson’s disease with L-Dopa and dopadecarboxylase inhibitor: therapeutic results and side effects Acta Neurol Scand 57 186-9

[8] Lindeman RD(1971)An attempt to include quality of life in evaluation of survival in bronchial cancer therapy Bronches 21 215-63

[9] Cooper C(1999)Assessing quality of life in clinical research from where have we come and where are we going? J Clin Epidemiol 52 355-22

[10] Dere W(1984)The development of a method for assessing the quality of life of cancer patients Br J Cancer 50 13-70